Table 2. Characteristics of the most central trials.

Network	Measure	Group	Disease	Treatment	Av. HR
Group, Treatment, Disease	Betweenness Max = 0.006	ECOG	Leukemia	Definitive*	1.22
	Closeness Max = 0.75	ECOG	GI	Definitive*	1.22
	Authorities Max = 0.08	ECOG	GI(8/10); GYN(2/10)	Definitive*	0.97
	Hubs Max = 0.08	ECOG	GI(8/10); GYN(2/10)	Definitive*	0.97
Random network based on the Group, Treatment, Disease network	Betweenness Max = 0.002	RTOG	Lung	Definitive*	0.98
	Closeness Max = 0.69	ECOG	Lung	Definitive*	0.98
	Authorities Max = 0.06	RTOT (3/10); ECOG (5/10); GOG (1/10); SWOG (1/10)	GI(3/10); Lung (2/10); GYN (2/10); H&N Leukemia	Definitive*(6/10); Adjuvant (2/10); Supportive(1/10); Other (2/10)	0.96
	Hubs Max = 0.06	RTOT (3/10); ECOG (5/10); GOG (1/10); SWOG (1/10)	GI(3/10); Lung (2/10); GYN (2/10); H&N Leukemia	Definitive*(6/10)Adjuvant (2/10)Supportive(1/10)Other (2/10)	0.96
Preferential attachment	Betweenness Max = 0.04	RTOG	Prostate	Definitive*	2.82
	Closeness Max = 0.66	ECOG	Lung	Definitive*	2.31
	Authorities Max = 0.18	ECOG	Lung	Definitive*	2.31
	Hubs Max = 0.18	ECOG	Lung	Definitive*	2.31
Random network based on the Preferential attachment network	Betweenness Max = 0.068	SWOG	GI	Adjuvant	0.75
	Closeness Max = 0.554	SWOG	GI	Adjuvant	0.75
	Authorities Max = 0.089	ECOG (5/10); SWOG (2/10); NCCTG (1/10); CALGB (1/10); CHOG (1/10)	GI (3/10); CNS (2/10); Lung (2/10); Leukemia (1/10); Melanoma (1/10); Breast (1/10)	Definitive*(5/10); Adjuvant (3/10) Maintenance (1/10) Other	1.10
	Hubs Max = 0.089	ECOG (5/10); SWOG (2/10); NCCTG (1/10); CALGB (1/10); CHOG (1/10)	GI (3/10); CNS (2/10); Lung (2/10); Leukemia (1/10); Melanoma (1/10) Breast (1/10)	Definitive*(5/10) Adjuvant (3/10) Maintenance (1/10) Other	1.10

For brevity, we do not include the networks generated by the shared characteristics: group, treatment; group, disease; disease, treatment. The numbers in parentheses denote the memberships of each component in the group of nodes that present the same centrality measures.